Evaluation of the Level of Satisfaction of Patients with the Use of a Newly Marketed Vaginal Gel (Satisvag Survey)

Santiago Palacios1, Fernando Losa2, Josep Combalia3, Carine Emsellem3, Yann Gaslain3 and Danial Khorsandi1,4,5*

1Palacios Institute of Women's Health and Medicine, Madrid, Spain
2Sagrada Familia Clinic, Barcelona, Spain
3Procare Health Iberia, Castelldefels, Barcelona, Spain
4University of Barcelona, Barcelona, Spain
5Harvard-MIT’s Division of Health Science and Technology, MA, USA

*Corresponding author: Danial Khorsandi, Universitat de Barcelona, Pharmacy and Pharmaceutical Technology, Campus Diagonal, Av. de Joan XXIII, 27-3 Barcelona Spain, Tel: +34617772262; E-mail: danialkhorsandi92@gmail.com

Received date: March 15, 2018; Accepted date: March 24, 2018; Published date: March 28, 2018

Copyright: © 2018 Palacios S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: To evaluate the general level of satisfaction of the patients in relation to the use of Palomacare®, a multi-ingredient, non-hormonal vaginal gel with moisturizing and restorative properties indicated for the improvement of symptoms and signs that make up the genitourinary syndrome, after its recent commercialization.

Methods: The satisvag survey was addressed during the first quarter of 2016 to Spanish gynaecologists who were visiting women that already were using Palomacare®. At the end, collected data were analyzed.

Results: A total of 62 doctors participated in the survey, ~ 90% of them had ≥5 patients using Palomacare®. 98% of survey respondents indicated the overall satisfaction with Palomacare® in their patients is good or excellent (Q2). Data concerning to both general comfort and general comparison to other products (Q3 and Q5) are shown in Figure 1.

Conclusion: After analyzing the data we assured that Palomacare® is a well-tolerated product with a comfortable application. Its specific features make the product use highly satisfactory and perceived as better than other previous treatments.

Introduction

For any product that is administered vaginally, both the comfort of application and the sensations of the patient are key factors to determine overall satisfaction. This has a direct impact on the adherence and, ultimately, the effectiveness of the prescribed treatment. Quickly understanding the advantages and disadvantages of a newly marketed product, could be useful to improve prescription habits and patient response [1-5].

Palomacare® is a multi-ingredient including Niosome and Phytosome particles, which contains Hyaluronic Acid and natural ingredients. This medical device marketed in Spain since July 2015 [6-9]. Vaginally applied in the form of a gel with moisturizing and restorative properties of the vaginal mucosa, it is indicated for improvement of symptoms and signs that make up the genitourinary syndrome.

The objective of this survey was to determine the opinion of doctors in relation to the overall satisfaction of patients with the use of Palomacare®, after its recent commercialization [10,11].

Methods

The Satisvag survey was conducted during the first quarter of 2016. A questionnaire of eight questions was performed related to the use of Palomacare® in clinical practice. The survey was targeted to Spanish gynecologists already prescribing Palomacare® to their patients and followed a homogeneous distribution across the country. Data quality was ensured through double-entry Microsoft Excel®.

Results

A total of 62 doctors participated in the survey, having the ~ 90% of them ≥5 patients using Palomacare®, 98% of survey respondents indicated the overall satisfaction with Palomacare® in their patients is good or excellent (Q2). Data concerning to both general comfort and general comparison to other products (Q3 and Q5) are shown in Figure 1.
95% indicated that absorption, understood as the absence of product loss, is good or excellent (Q4). The main advantages of Palomacare® highlighted by users, especially compared to previous products are shown in Figure 2 (Q6). Nearly 90% of doctors said that no patient reported any adverse effect (Q7). Stinging/burning was indicated as the most common adverse effect observed.

**Discussion**

Palomacare® is a well-tolerated product with a comfortable application. Its specific features make the product use highly satisfactory and perceived as better than other previous treatments.

**References**